---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028748"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:07:21.893849+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# InfuSystem reports record Q3 revenue $27.3M; net income turns positive; FY guidance at low end

## Summary
- Record Q3 net revenue $27.3M (+3% YoY); ITS segment revenue record $17.4M (+5% YoY).
- Net income $0.4M ($0.02/diluted) vs net loss $0.4M in prior-year quarter; operating income up $1.3M to $0.9M.
- Gross margin improved 200 bps to 59.5%; ITS gross margin 65.6%, DME 48.7%.
- FY2022 guidance: revenue ~$112M (low end of prior 10-13% growth); Adj. EBITDA ~$22M (19-20% margin).
- Nov 3: formed wound therapy partnership with Sanara MedTech and signed distribution agreement with Cork Medical.

## SEC filing metadata
- accession: 0001628280-22-028748
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/0001628280-22-028748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/infu-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028748
- JSON: https://secwatch.observer/filing/0001628280-22-028748.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028748.txt

## Key facts
- Earnings Releases
  InfuSystem Holdings, Inc reported the third quarter ended September 30, 2022 results: revenue $27.3 million, net income $0.4 million, EPS $0.02 per diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $27.3 million
  - Net income: $0.4 million
  - EPS: $0.02 per diluted share
  - Result: reported results
  source text: • Net revenues totaled $27.3 million, an increase of 3% vs. prior year. ◦ Integrated Therapy Services ("ITS") net revenue was $17.4 million, an increase of 5% vs. prior year. ◦ Durable Medical Equipment Services ("DME Services") net revenue was $9.9 million, a decrease of 1% vs. prior year. • Gross profit was $16.2 million, an increase of 6% vs. prior year. • Gross margin was 59.5%, an increase of 2.0% vs. prior year. ◦ ITS gross margin was 65.6%, an increase of 1.8% vs. prior year. ◦ DME Services gross margin was 48.7%, an increase of 1.7% vs. prior year. • Operating income increased $1.3 million to $0.9 million vs. prior year. • Net income of $0.4 million, or $0.02 per diluted share, an increase of $0.9 million vs. prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/0001628280-22-028748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.